Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 open-label first-in-human dose escalation trial of AL102 in combination WVT078 for the treatment of patients with relapsed and/or refractory multiple myeloma (MM)

Next Previous
Trial Profile

Phase 1 open-label first-in-human dose escalation trial of AL102 in combination WVT078 for the treatment of patients with relapsed and/or refractory multiple myeloma (MM)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BMS 986115 (Primary) ; WVT 078 (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Novartis

Most Recent Events

  • 21 Apr 2021 According to an Ayala Pharmaceuticals media release, first patient has been dosed in this trial.
  • 21 Apr 2021 Status changed from planning to recruiting, according to an Ayala Pharmaceuticals media release.
  • 05 Jan 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top